Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call
October 26, 2017 07:00 ET
|
Apricus Biosciences, Inc.
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences to Present at the 2017 BIO Investor Forum
October 10, 2017 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market
September 11, 2017 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it...
Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 05, 2017 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA Resubmission
August 31, 2017 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the...
Apricus Biosciences Files NDA Resubmission for Vitaros™
August 29, 2017 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported that it...
Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results
August 02, 2017 16:01 ET
|
Apricus Biosciences
Vitaros Drug-Device Human Factor Studies Successfully Completed Vitaros U.S. NDA Final Draft Completed with Re-Submission Expected in Current Quarter Conference Call / Webcast Today, August 2, 2017...
Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call
July 26, 2017 07:00 ET
|
Apricus Biosciences
SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results
May 11, 2017 16:01 ET
|
Apricus Biosciences
Vitaros U.S. NDA Re-Submission Remains on Track for Third Quarter 2017 Vitaros Drug-Device Human Factor Studies Underway Operations Funded Through the Third Quarter of 2018 Conference Call /...
Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study
May 04, 2017 07:00 ET
|
Apricus Biosciences
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported that the...